211 related articles for article (PubMed ID: 25405533)
1. Erythropoietin as a new therapeutic opportunity in brain inflammation and neurodegenerative diseases.
Merelli A; Czornyj L; Lazarowski A
Int J Neurosci; 2015; 125(11):793-7. PubMed ID: 25405533
[TBL] [Abstract][Full Text] [Related]
2. The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans.
Garcia-Rodriguez JC; Sosa-Teste I
ScientificWorldJournal; 2009 Sep; 9():970-81. PubMed ID: 19768354
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin: a neuroprotective agent in cerebral hypoxia, neurodegeneration, and epilepsy.
Merelli A; Czornyj L; Lazarowski A
Curr Pharm Des; 2013; 19(38):6791-801. PubMed ID: 23530506
[TBL] [Abstract][Full Text] [Related]
4. Experimental evidence of the potential use of erythropoietin by intranasal administration as a neuroprotective agent in cerebral hypoxia.
Merelli A; Caltana L; Lazarowski A; Brusco A
Drug Metabol Drug Interact; 2011; 26(2):65-9. PubMed ID: 21756166
[TBL] [Abstract][Full Text] [Related]
5. Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ₂₅₋₃₅ non-transgenic mouse model of Alzheimer's disease.
Maurice T; Mustafa MH; Desrumaux C; Keller E; Naert G; de la C García-Barceló M; Rodríguez Cruz Y; Garcia Rodríguez JC
J Psychopharmacol; 2013 Nov; 27(11):1044-57. PubMed ID: 23813967
[TBL] [Abstract][Full Text] [Related]
6. Intranasal erythropoietin ameliorates neurological function impairments and neural pathology in mice with chronic alcoholism by regulating autophagy‑related Nrf2 degradation.
Nie X; Wang W; Wang Q; Zhu D; Song H
Mol Med Rep; 2019 Feb; 19(2):1139-1149. PubMed ID: 30535439
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin and derivatives: Potential beneficial effects on the brain.
Vittori DC; Chamorro ME; Hernández YV; Maltaneri RE; Nesse AB
J Neurochem; 2021 Sep; 158(5):1032-1057. PubMed ID: 34278579
[TBL] [Abstract][Full Text] [Related]
8. Targeting erythropoietin for chronic neurodegenerative diseases.
Chong ZZ; Shang YC; Mu Y; Cui S; Yao Q; Maiese K
Expert Opin Ther Targets; 2013 Jun; 17(6):707-20. PubMed ID: 23510463
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia, Oxidative Stress, and Inflammation: Three Faces of Neurodegenerative Diseases.
Merelli A; Repetto M; Lazarowski A; Auzmendi J
J Alzheimers Dis; 2021; 82(s1):S109-S126. PubMed ID: 33325385
[TBL] [Abstract][Full Text] [Related]
10. Activity increase in EpoR and Epo expression by intranasal recombinant human erythropoietin (rhEpo) administration in ischemic hippocampi of adult rats.
Castañeda-Arellano R; Feria-Velasco AI; Rivera-Cervantes MC
Neurosci Lett; 2014 Nov; 583():16-20. PubMed ID: 25219375
[TBL] [Abstract][Full Text] [Related]
11. Development of a Neuroprotective Erythropoietin Modified with a Novel Carrier for the Blood-Brain Barrier.
Chiu PC; Liou HC; Ling TY; Shen LJ
Neurotherapeutics; 2020 Jul; 17(3):1184-1196. PubMed ID: 32144722
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system.
Sirén AL; Fasshauer T; Bartels C; Ehrenreich H
Neurotherapeutics; 2009 Jan; 6(1):108-27. PubMed ID: 19110203
[TBL] [Abstract][Full Text] [Related]
13. Nasal neuro EPO could be a reliable choice for neuroprotective stroke treatment.
Parra AL; Rodriguez JC
Cent Nerv Syst Agents Med Chem; 2012 Mar; 12(1):60-8. PubMed ID: 22376076
[TBL] [Abstract][Full Text] [Related]
14. Protective action of erythropoietin on neuronal damage induced by activated microglia.
Wenker SD; Chamorro ME; Vittori DC; Nesse AB
FEBS J; 2013 Apr; 280(7):1630-42. PubMed ID: 23384249
[TBL] [Abstract][Full Text] [Related]
15. Intranasal erythropoietin therapy in nervous system disorders.
Genc S; Zadeoglulari Z; Oner MG; Genc K; Digicaylioglu M
Expert Opin Drug Deliv; 2011 Jan; 8(1):19-32. PubMed ID: 21143002
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin 2nd cerebral protection after acute injuries: a double-edged sword?
Velly L; Pellegrini L; Guillet B; Bruder N; Pisano P
Pharmacol Ther; 2010 Dec; 128(3):445-59. PubMed ID: 20732352
[TBL] [Abstract][Full Text] [Related]
17. [Erythropoietin--a new therapy in cerebral ischemia?].
Kalialis LV; Olsen NV
Ugeskr Laeger; 2003 Jun; 165(24):2477-81. PubMed ID: 12872467
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin and Nonhematopoietic Effects.
Nekoui A; Blaise G
Am J Med Sci; 2017 Jan; 353(1):76-81. PubMed ID: 28104107
[TBL] [Abstract][Full Text] [Related]
19. The relationship between erythropoietin pretreatment with blood-brain barrier and lipid peroxidation after ischemia/reperfusion in rats.
Bahcekapili N; Uzüm G; Gökkusu C; Kuru A; Ziylan YZ
Life Sci; 2007 Mar; 80(14):1245-51. PubMed ID: 17300815
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin and the hypoxic brain.
Marti HH
J Exp Biol; 2004 Aug; 207(Pt 18):3233-42. PubMed ID: 15299044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
